MetaCap

Ultragenyx Pharmaceutical Inc. (RARE)

NASDAQ: RAREHealth CareBiotechnology: Pharmaceutical PreparationsUSD

16.48-0.74 (-4.30%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

RARE stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$5.17
52-week range
12.73 – 39.89
Day range
16.43 – 17.35
Volume / Avg
3.01M / 4.69M
Beta
—

52-week range

$12.73$39.89

RARE stock today

On Nov 20, RARE ended the session at $16.48, shedding $0.74 (4.30%), versus the S&P 500's 3.70% decline. At this level, RARE sits near the bottom of its 52-week range of $12.73 to $39.89: 58.7% below the high, set on Dec 8, 2025 and 29.5% above the low. RARE is down 28.3% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 50.9%.

Ultragenyx Pharmaceutical has posted a net loss over the last twelve months (EPS of -$5.17), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Ultragenyx Pharmaceutical

Company profile

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Emil D. Kakkis M.D., Ph.D.
Headquarters
Novato, CA
Employees
1,371
IPO year
2014

Financial highlights

Full financials

In fiscal 2025, Ultragenyx Pharmaceutical generated $673.0 million in revenue, up 20.2% from fiscal 2024, its 9th consecutive year of revenue growth. Ultragenyx Pharmaceutical reported a net loss of $575.0 million, compared with a loss of $569.0 million a year earlier. Operating margin was -79.5%.

Ultragenyx Pharmaceutical annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$673.00M$560.00M$434.00M$363.33M$351.41M
Growth+20.18%+29.03%+19.45%+3.39%+29.66%
Net income$-575.00M$-569.00M$-607.00M$-707.42M$-454.02M
EPS (diluted)$-5.83$-6.29$-8.25$-10.12$-6.70

Analyst forecast

Forecast

Consensus (21 analysts)

buy

Avg. price target

$24.80+50.49%

  • Strong buy 2
  • Buy 8
  • Hold 11
  • Sell 0
  • Strong sell 0

Target range

Low $16.00High $39.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 3, 2026
EPS actual vs est.
$-1.81 vs $-1.15
Surprise
-57.39%

RARE news

All RARE news

Ultragenyx Pharmaceutical peers

Health Care sector
RARE peer companies
CompanyPrice% ChgMarket capCompare
BRVEBraveheart Bio Inc.20.39+5.81%$1.67Bvs RARE
AGIOAgios Pharmaceuticals Inc.27.60-4.03%$1.65Bvs RARE
KRSAKorsana Biosciences Inc.37.56+5.95%$1.71Bvs RARE
SDGRSchrodinger Inc.22.93-12.95%$1.72Bvs RARE
ZBIOZenas BioPharma Inc.23.85-4.75%$1.62Bvs RARE
TRAXFirst Tracks Biotherapeutics Inc.41.64-6.34%$1.75Bvs RARE
STOKStoke Therapeutics Inc.26.81-0.45%$1.75Bvs RARE
ETONEton Pharmaceuticals Inc.60.85-0.83%$1.76Bvs RARE

Indexes, lists and sector

Ultragenyx Pharmaceutical stock FAQ

What is Ultragenyx Pharmaceutical's stock price today?

RARE last traded at $16.48 as of Nov 20, 4:00 PM EST, down 4.30% on the day. Prices are delayed at least 15 minutes.

Who is Ultragenyx Pharmaceutical's CEO?

Dr. Emil D. Kakkis M.D., Ph.D. is the chief executive officer of Ultragenyx Pharmaceutical Inc., which has about 1,371 employees.

What is the RARE 52-week high?

The 52-week high for RARE is $39.89 and the 52-week low is $12.73. The stock is currently 58.7% below its high.

Compare RARE